Asieris Pharmaceuticals, a China-based biotech company, has received approval for its Phase I clinical trial of APL-1501 from the Australian regulatory authorities, it was reported on Wednesday.
The aim of this Phase I study is to assess APL-1501's safety, tolerability, and pharmacokinetic characteristics for the treatment of non-muscle invasive bladder cancer (NMIBC).
The product has been independently developed by the company's Prodrug Accurate Drug Delivery platform and is an oral sustained-release product based on APL-1202 and will be the second-generation product of APL-1202 to support new clinical development globally. It inherits the oral administration of APL-1202 and the druggability of APL-1501 and has been improved by the design of prodrug molecules.
Harbour BioMed partner raises USD225m to advance neoadjuvant immuno-oncology therapy porustobart
Kazia Therapeutics doses first patient in paediatric AT/RT study
Fusion Antibodies secures Canadian patent for OptiMAL
Revvity to acquire Human Cell Design to expand metabolic disease drug discovery capabilities
Biophytis expands BIO101 obesity study to assess weight regain
THX Pharma secures European patent for Batten-1 in juvenile Batten disease
Orphalan commences Phase 3 study of trientine therapy in Wilson disease
ZAGENO named Frost & Sullivan's 2026 North American Life Sciences E-Commerce Company of the Year
Pharvaris reports Phase 3 success for deucrictibant XR in HAE prophylaxis
Sky Labs presents clinical research outcomes for ring-type blood pressure monitor CART